Innovate UK accelerates Sareum’s fight against Leukemia

17/06/2015 - 2 minutes

Innovate UK, the country’s innovation agency, keeps promoting technology in the British islands. The latest beneficiary is Sareum, a cancer specialist biotech with a strong autoimmune disease programme. The company received €195.5k to fight an early-age type of leukaemia.

T-Cell Acute Lymphoblastic Leukaemia is a rare type of leukaemia that most often occurs in late childhood and early adolescence. The disease, that affects T-cells, is aggressive and progresses quickly. Around 200 people are diagnosed with this type of leukemia in the UK every year.

According to the literature, TYK2 inhibition may embody a solution for treating leukemia. Sareum has previously demonstrated the efficacy of its lead TYK2 molecules in models of autoimmune diseases, such as psoriasis and multiple sclerosis, in collaboration with SRI International. This funding award will enable Sareum to further determine the feasibility of this novel approach.

The award is part of the Biomedical Catalyst, an integrated translational funding programme, jointly operated by the Medical Research Council and Innovate UK. The Catalyst model supports projects in priority areas where the UK research base has a leading position and where there is a clear commercial potential.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member